3-D QSAR studies on histone deacetylase inhibitors. A GOLPE/GRID approach on different series of compounds

Journal of Chemical Information and Modeling

Volumn 46, Issue 3, 2006, Pages 1420-1430

  Ragno, Rino ^a   Simeoni, Silvia ^a   Valente, Sergio ^a   Massa, Silvio ^b   Mai, Antonello ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; ENZYME INHIBITION; MATHEMATICAL MODELS; STATISTICAL METHODS;

MOLECULAR DIVERSITY; QSAR MODELS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS; STRUCTURAL REQUIREMENTS;

ENZYMES;

ENZYME INHIBITOR; HISTONE DEACETYLASE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ENZYME INHIBITORS; HISTONE DEACETYLASES; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745356936     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci050556b     Document Type: Article

References (58)

1. Doenecke, D.; Gallwitz, D. Acetylation of histones in nucleosomes. Mol. Cell. Biochem. 1982, 44, 113-28.
2. Loidl, P. Histone acetylation: facts and questions. Chromosoma 1994, 103, 441-9.
3. Lopez-Rodas, G.; Brosch, G.; Georgieva, E. I.; Sendra, R.; Franco, L.; Loidl, P. Histone deacetylase. A key enzyme for the binding of regulatory proteins to chromatin. FEBS Lett. 1993, 317, 175-80.
4. Magnaghi-Jaulin, L.; Ait-Si-Ali, S.; Harel-Bellan, A. Histone acetylation and the control of the cell cycle. Prog. Cell. Cycle Res. 2000, 4, 41-7.
5. Kayne, P. S.; Kim, U. J.; Han, M.; Mullen, J. R.; Yoshizaki, F.; Grunstein, M. Extremely conserved histone H4 N terminus is dispensable for growth but essential for repressing the silent mating loci in yeast. Cell 1988, 55, 27-39.
6. Rusche, L. N.; Kirchmaier, A. L.; Rine, J. The establishment, inheritance, and function of silenced chromatin in Saccharomyces cerevisiae. Annu. Rev. Biochem. 2003, 72, 481-516.
7. Archer, S. Y.; Hodin, R. A. Histone acetylation and cancer. Curr. Opin. Genet. Dev. 1999, 9, 171-4.
8. Brown, R.; Strathdee, G. Epigenomics and epigenetic therapy of cancer. Trends Mol. Med. 2002, 8, S43-8.
9. Davis, P. K.; Brackmann, R. K. Chromatin remodeling and cancer. Cancer Biol. Ther. 2003, 2, 22-9.
10. Laird, P. W. Cancer epigenetics. Hum. Mol. Genet. 2005, 14 Spec. No. 1, R65-76.
11. Tycko, B. Epigenetic gene silencing in cancer. J. Clin. Invest. 2000, 105, 401-7.
12. Marks, P.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 7, 194-202.
13. Saunders: N.; Dicker, A.; Popa, C.; Jones, S.; Dahler, A., Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. 1999, 59, 399-404.
14. Greenberg, V. L.; Williams, J. M.; Cogswell, J. P.; Mendenhall, M.; Zimmer, S. G. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 2001, 11, 315-25.
15. Jung, M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 2001, 8, 1505-11.
16. Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; Ragno, R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 2005, 25, 261-309.
17. De Rubertis, F.; Kadosh, D.; Henchoz, S.; Pauli, D.; Reuter, G.; Struhl, K.; Spierer, P. The histone deacetylase RPD3 counteracts genomic silencing in Drosophila and yeast. Nature 1996, 384, 589-91.
18. Rundlett, S. E.; Carmen, A. A.; Kobayashi, R.; Bavykin, S.; Turner, B. M.; Grunstein, M. HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 14503-8.
19. Carmen, A. A.; Rundlett, S. E.; Grunstein, M. HDA1 and HDA3 are components of a yeast histone deacetylase (HDA) complex. J. Biol. Chem. 1996, 271, 15837-44.
20. Brachmann, C. B.; Sherman, J. M.; Devine, S. E.; Cameron, E. E.; Pillus, L.; Boeke, J. D. The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev. 1995, 9, 2888-902.
21. Gotta, M.; Strahl-Bolsinger, S.; Renauld, H.; Laroche, T.; Kennedy, B. K.; Grunstein, M.; Gasser, S. M. Localization of Sir2p: the nucleolus as a compartment for silent information regulators. Embo. J. 1997, 16, 3243-55.
22. Gregoretti, I. V.; Lee, Y. M.; Goodson, H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 2004, 338, 17-31.
23. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-9.
24. Butler, L. M.; Agus, D. B.; Scher, H. I.; Higgins, B.; Rose, A.; Cordon-Cardo, C.; Thaler, H. T.; Rifkind, R. A.; Marks, P. A.; Richon, V. M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000, 60, 5165-70.
25. Richon, V. M.; Zhou, X.; Rifkind, R. A.; Marks, P. A. Histone deacetylase inhibitors: development of Suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol. Dis. 2001, 27, 260-4.
26. Bedalov, A.; Gatbonton, T.; Irvine, W. P.; Gottschling, D. E.; Simon, J. A. Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 15113-8.
27. Brosch, G.; Lusser, A.; Goralik-Schramel, M.; Loidl, P. Purification and characterization of a high molecular weight histone deacetylase complex (HD2) of maize embryos. Biochemistry 1996, 35, 15907-14.
28. Mai, A.; Massa, S.; Cerbara, I.; Valente, S.; Ragno, R.; Bottoni, P.; Scatena, R.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl) N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity. J. Med. Chem. 2004, 47, 1098-109.
29. Jung, M.; Brosch, G.; Kolle, D.; Scherf, H.; Gerhauser, C.; Loidl, P. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem. 1999, 42, 4669-79.
30. Wittich, S.; Scherf, H.; Xie, C.; Brosch, G.; Loidl, P.; Gerhauser, C.; Jung, M. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J. Med. Chem. 2002, 45, 3296-309.
31. Mai, A.; Massa. S.; Pezzi, R.; Rotili, D.; Loidl, P.; Brosch, G. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J. Med. Chem. 2003, 46, 4826-9.
32. Mai, A.; Massa, S.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio, A.; Altucci, L.; Loidl, P.; Brosch, G. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem. 2005, 48, 3344-53.
33. Mai, A.; Massa, S.; Ragno, R.; Cerbara, I.; Jesacher, F.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1 -methyl-1 H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. J. Med. Chem. 2003, 46, 512-24.
34. Mai, A.; Massa, S.; Ragno, R.; Esposito, M.; Sbardella, G.; Nocca, G.; Scatena, R.; Jesacher, F.; Loidl, P.; Brosch, G. Binding mode analysis of 3-(4-benzoyl-1-methyl-1 H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. J. Med. Chem. 2002, 45, 1778-84.
35. Mai, A.; Massa, S.; Rotili, D.; Pezzi, R.; Bottoni, P.; Scatena, R.; Meraner, J.; Brosch, G. Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. Bioorg. Med. Chem. Lett. 2005, 15, 4656-61.
36. Massa, S.; Mai, A.; Sbardella, G.; Esposito, M.; Ragno, R.; Loidl, P.; Brosch, G. 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. J. Med. Chem. 2001, 44, 2069-72.
37. Ragno, R.; Mai, A.; Massa, S.; Cerbara, I.; Valente, S.; Bottoni, P.; Scatena, R.; Jesacher, F.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1-methyl1H-pyrrol-2- yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. J. Med. Chem. 2004, 47, 1351-9.
38. Xie, A.; Liao, C.; Li, Z.; Ning, Z.; Hu, W.; Lu, X.; Shi, L.; Zhou, J. Quantitative structure-activity relationship study of histone deacetylase inhibitors. Curr. Med. Chem. Anti-Cancer Agents 2004, 4, 273-99.
39. Cramer, R. D., III.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-67.
40. Cruciani, G.; Watson, K. A. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. J. Med. Chem. 1994, 37, 2589-601.
41. Liu, B.; Lu, A.-J.; Liao, C.-Z.; Liu, H.-B.; Zhou, J.-J. 3D-QSAR of sulfonamide hydroxamic acid HDAC inhibitors. Wuli Huaxue Xuebao 2005, 21, 337.
42. Chen, H.-f.; Kang, J.-h.; Li, Q.; Zeng, B.-s.; Yao, X.-j.; Fan, B.-t.; Yuan, S.-g.; Panay, A.; Doucet, J. P. 3D-QSAR study on apicidin inhibit histone deacetylase. Chin. J. Chem. 2003, 21, 1596-1607.
43. Guo, Y.; Xiao, J.; Guo, Z.; Chu, F.; Cheng, Y.; Wu, S. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses. Bioorg. Med. Chem. 2005, 13, 5424-34.
44. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37, 4130-46.
45. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-93.
46. Ragno, R.; Marshall, G. R.; Di Santo, R.; Costi, R.; Massa, S.; Rompei, R.; Artico, M. Antimycobacterial pyrroles: synthesis, anti-Mycobacterium tuberculosis activity and QSAR studies. Bioorg. Med. Chem. 2000, 8, 1423-32.
47. Di Santo, R.; Costi, R.; Artico, M.; Massa, S.; Ragno, R.; Marshall, G. R.; La Colla, P. Design, synthesis and QSAR studies on N-aryl heteroarylisopropanolamines, a new class of non-peptidic HIV-1 protease inhibitors. Bioorg. Med. Chem. 2002, 10, 2511-26.
48. Tafi, A.; Anastassopoulou, J.; Theophanides, T.; Botta, M.; Corelli, F.; Massa, S.; Artico, M.; Costi, R.; Di Santo, R.; Ragno, R. Molecular modeling of azole antifungal agents active against Candida albicans. 1. A comparative molecular field analysis study. J. Med. Chem. 1996, 39, 1227-35.
49. Wold, S.; Johansson, E.; Cocchi, M. PSL - partial least-squares projections to latent structures. 3D QSAR Drug Des. 1993, 523-50.
50. Clark, M.; Cramer, R. D., III The probability of chance correlation using partial least squares (PLS). Quant. Struct. - Act. Relat. 1993, 12, 137-45.
51. Cruciani, G.; Baroni, M.; Clementi, S.; Costantino, G.; Riganelli, D.; Skagerberg, B. Predictive ability of regression models. Part I. Standard deviation of prediction errors (SDEP). J. Chemom. 1992, 6, 335-46.
52. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel-An Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics. J. Comput. Chem. 1990, 11, 440-467.
53. Berman, H.; Henrick, K.; Nakamura, H. Announcing the worldwide Protein Data Bank. Nat. Struct. Biol. 2003, 10, 980.
54. Stewart, J. J. P. MOPAC 2000; Fujitsu Limited: Tokyo, Japan, 1999.
55. Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, I., Thomas E.; DeBolt, S.; Ferguson, D.; Seibel, G.; Kollman, P. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput. Phys. Commun. 1995, 91, 1-41.
56. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-57.
57. GOLPE; Multivariate Infometric Analysis Sri., Viale del Castagni 16, Perugia, Italy, 1999.
58. Baroni, M.; Costantino, G.; Cruciani, G.; Riganelli, D.; Valigi, R.; Clementi, S. Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems. Quant. Struct.-Act. Relat. 1993, 12, 9-20.